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Introduction
Ovarian cancer is one of the leading causes of cancer deaths 
among women in United States and Europe. Epithelial ovarian 
carcinomas (EOCs) are the most common ovarian cancers ac-
counting for 90% of cases and primarily classified according 
to cell type into mucinous, serous, clear cell, endometrioid, 
transitional, and squamous cell carcinoma [1]. Because the 
symptom is not apparent until advanced disease, most EOC 
patients diagnosed in stage III or IV when little treatment can 
be done to cure this disease. Thus, it is of utmost importance 
to find an efficient, non-invasive, and highly specific diagnos-
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The main aim of this study was to evaluate cancer antigen 125 (CA125)/carcinoembryonic antigen (CEA) ratio (CCR), 
as a reliable marker to differentiate ovarian mucinous carcinoma from other epithelial ovarian carcinomas (EOCs), 
namely serous, clear cell, and endometrioid carcinomas.
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84.4%, respectively in stage II–IV (both cut-off value <90.7).
Conclusion
The present results suggest that pretreatment CCR might provide higher specificity and clinically relevant information 
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tic methods for the women presenting with pelvic masses. 
Biochemical markers might have these diagnostic criteria and 
can be useful for screening, diagnosis, prognosis, monitor-
ing, staging, as well as the management of various cancers, 
including ovarian cancers [2]. 
Cancer antigen 125 (CA125), the most widespread marker 
of EOCs, is a glycoprotein encoded by MUC16 gene on chro-
mosome 19 [3]. The expression of CA125 has been reported 
to be elevated in 85% of serous, 65% of endometrioid, 
40% of clear cell, and 36% of undifferentiated, but it was 
elevated only in 12% of ovarian mucinous carcinomas [3,4]. 
In addition, CA125 have been reported to also increase in 
patients with other gynecological diseases such as myomas 
of the uterus, benign and borderline ovarian tumors, many 
non-gynecological illnesses (e.g., hepatic cirrhosis, congeni-
tal heart defects), during pregnancy, and even in 1–5% of 
healthy women [5,6]. Thus, CA125 alone might not be a 
highly specific diagnostic tool for ovarian cancer, especially 
for mucinous type and it is necessary to find another marker, 
which can better discriminate ovarian pelvic mass preopera-
tively and to differentiate between mucinous and other types 
of EOC.
Carcinoembryonic antigen (CEA) is a glycoprotein that is 
synthesized in fetal tissues and in some carcinomas such as 
colorectal carcinoma [7]. Some groups advocate utilizing 
CEA as a potential marker for monitoring ovarian cancer, 
especially when CA125 is not elevated [2]. The cells of ovar-
ian mucinous carcinoma may resemble those of the gastric 
pylorus, intestine, or endocervix [1]. In recent studies of 
comparing primary ovarian mucinous carcinomas with meta-
static colorectal carcinomas, 67–85% of ovarian mucinous 
carcinomas were CEA positive [8-10]. In addition, it has been 
previously suggested that CA125/CEA ratio (CCR) might dif-
ferentiate between ovarian and other pelvic masses, where 
values >25 are most probably ovarian tumors and values <25 
are most probably other pelvic masses [11]. Thus, it is reason-
able to hypothesize that CCR might be a good biomarker to 
differentiate ovarian mucinous carcinoma from other types 
of EOC.
The purpose of the present study was to determine wheth-
er preoperative serum CCR might be a strong biomarker, for 
preoperative differential diagnosis between ovarian mucinous 
carcinoma and other types of carcinomas, namely serous, 
clear cell, and endometrioid carcinomas by analyzing serum 
levels from female patients diagnosed with these carcinomas. 
Materials and methods
1. Patients and histology
Patients who underwent elective surgery at the Gangnam 
Severance Hospital between January 2008 and December 
2016, were included in this study. Of the individuals with 
EOCs, 30 (16.8%) had mucinous, 100 (28.0%) had serous, 
24 (13.5%) had clear cell, and 24 (13.5%) had endometrioid 
carcinoma. All EOC patients were surgically staged according 
to the International Federation of Gynecology and Obstet-
rics staging system [12]. All stage I–IV patients had staging 
laparotomy according to the National Comprehensive Cancer 
Network clinical practice guidelines.
2. Clinical and laboratory data collection
For all study subjects, CA125 and CEA levels were evaluated 
at primary diagnosis up to 10 days prior to surgery. CA125 
and CEA were measured with electrochemiluminescence 
immunoassay on the Roche/Hitachi Modular Analytics E170 
(Roche Diagnostics, Tokyo, Japan). Age, stage, cell types, 
body mass index (BMI), and parity were recorded for all 
study subjects. The CCR was defined as the CA125 divided 
by CEA. 
3. Statistical analysis 
Serum CA125, CEA, and CCR levels among study group 
(mucinous, serous, clear cell, and endometrioid type) for 
stage I and among the same groups for stage II–IV carcino-
ma were analyzed using analysis of variance post hoc tests. 
Receiver operating characteristics (ROC) analysis was used 
for specificity and sensitivity estimates. The resulting area 
under the curve (AUC) indicates the average sensitivity of 
marker over the entire ROC curve for mucinous carcinoma 
vs. other types of EOCs. The diagnostic values of CA125, 
CEA, and CCR were evaluated and the optimal cut-off val-
ues of for each parameter were determined to differentiate 
between mucinous carcinoma and other types of EOCs. 
ROC analysis was plotted to investigate the optimal cut-off 
values that maximized the sum of sensitivity and specificity. 
Statistical analysis was performed with the SPSS statistical 
software package, version 23.0 (SPSS Inc., Chicago, IL, USA). 
P<0.05 was considered to indicate a statistically significant 
difference.
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Results
Patient’s characteristics for each of the 178 cases are sum-
marized in Table 1. The mean age of patients at time of diag-
nosis was 46.8 years (range 31–60), the mean parity was 1.6, 
and the mean BMI was 23.6.
The evaluation of CA125 levels for stage I EOC patients 
showed that the mean CA125 for mucinous carcinoma ex-
hibited the lowest value (44.2 U/mL) among study groups 
(serous: 235.0 U/mL, clear cell: 86.9 U/mL, endometrioid: 
153.1 U/mL) and it was significantly lower than that of se-
rous carcinoma (P<0.05) (Fig. 1A, left panel). Similarly, for 
stages II–IV group, mucinous carcinoma patients had the 
lowest CA125 value (176.7 U/mL), compared to serous 
(1,709.0 U/mL) (P<0.01), clear cell (340.9 U/mL), and endo-
metrioid carcinoma (720.3 U/mL) (Fig. 1A, right panel).
The evaluation of CEA level showed that the mean CEA 
in stage I mucinous carcinoma was 2.4 ng/mL, while it was 
3.9 ng/mL for serous, 0.7 ng/mL for clear cell, and 1.3 ng/mL 
for endometrioid carcinoma (Fig. 1B, left panel). The level of 
CEA in mucinous carcinoma was significantly higher than 
that of clear cell and endometrioid carcinoma in stage I 
group (all P<0.01) (Fig. 1B, left panel). In stages II–IV group, 
the mean CEA of mucinous carcinomas (108.3 ng/mL) was 
remarkably highest among study groups (serous: 1.9 ng/mL, 
clear cell: 3.4 ng/mL, and endometrioid: 1.1 ng/mL) but there 
was no statistical significance (Fig. 1B, right panel). 
Because the mean levels of CA125 and CEA in mucinous 
carcinoma were significantly different from those of other 
types of EOC, we calculated CCR and evaluated the diag-
nostic significance of CCR. Our analysis showed that CCR in 
mucinous carcinoma (32.1) was remarkably lowest among 
stage I study group (serous: 154.0, clear cell: 235.0, and 
endometrioid: 427.0) and there was a statistically significant 
difference in clear cell (P<0.05) and endometrioid carcinoma 
(P<0.05) (Fig. 1C, left panel). Similarly, the mean CCR of 
mucinous carcinoma was lowest (37.6) among study group 
(serous: 148.0, clear cell: 694.0, and endometrioid: 494.2) in 
Table 1. Patient characteristics (mean level of age, parity, body mass index) with epithelial ovarian carcinoma (n=178)
Tumor type No. of patients (%) Age (yr) Parity BMI (kg/m2)
Mucinous carcinoma 30 (16.8) 44 1.3 23.9
I 22 (12.3) 42 1.0 23.5
II 2 (1.1) 46 2.5 27.0
III 5 (2.8) 51 2.6 24.1
IV 1 (0.6) 59 2.0 24.4
Serous carcinoma 100 (56.2) 58 2.0 23.7
I 14 (9.4) 57 1.8 24.5
II 3 (1.4) 44 0.6 23.4
III 71 (39.5) 60 2.7 24.1
IV 12 (5.9) 55 2.5 22.4
Clear cell carcinoma 24 (13.5) 47 1.4 22.9
I 16 (8.9) 48 1.4 21.6
II 1 (0.7) 48 2.0 22.5
III 4 (2.3) 45 1.5 27.6
IV 3 (1.6) 48 1.5 23.3
Endometrioid carcinoma 24 (13.5) 45 1.1 23.6
I 19 (10.7) 46 1.2 23.5
II 2 (1.2) 31 1.6 28.5
III 3 (1.6) 49 0.6 21.3
IV 0 (0)
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stages II–IV and there was statistically significant difference in 
serous type (P<0.01) (Fig. 1C, right panel).
To further compare the utility of CCR, CA125, and CEA in 
differentiating mucinous carcinoma from other types of EOC, 
we also analyzed the ROC curve. To categorize patients as 
CCR positive or negative, an optimal cut-off value that maxi-
mized the sum of sensitivity and specificity in the ROC curve 
was used. In case of CA125 and CEA, a known cut-off value 
of 35 U/mL and 5.0 ng/mL was used for analysis of diagnos-
tic power, respectively.
In case of CA125, the AUC for CCR in stage I was 0.6667 
(95% confidence interval [CI], 0.9–1.0) with a sensitivity 
of 72.7% and specificity of 64.5%, while it was 0.8345 
in stages II–IV with a sensitivity of 87.5% and specificity 
of 77.1% (Fig. 2A and Table 2). In case of CEA, the AUC 
for CCR in stage I was 0.7819 (95% CI, 0.9–1.0) with a 
sensitivity of 95.0% and specificity of 60.0%, while it was 
0.7250 (95% CI, 0.9–1.0) in stages II–IV with a sensitivity of 
83.3% and specificity of 60.0% (Fig. 2B and Table 2). We 
finally evaluated the CCR for mucinous carcinoma vs. other 
types of EOCs. The AUC for CCR in stage I was 0.7838 (95% 
CI, 0.9–1.0) with a sensitivity of 75.0% and specificity of 
77.5%, while it was 0.9167 (95% CI, 0.9–1.0) in stages II–
IV with a sensitivity of 100% and specificity of 84.4% and 
the cut-off value was <90.7 for mucinous carcinoma for all 
stages (Fig. 2C and Table 2). The positive predictive value 
(PPV) and negative predictive value (NPV) for CCR was 59.7% 
and 87.3%, respectively in stage I, while it was 14.2% and 
97.7%, respectively in stages II–IV group (Table 2). Taken 
together, the current study suggests that the utility of CCR 
might be a good differentiating tool between mucinous car-
cinoma and other types of EOCs, supporting our hypothesis.
Discussion
Numerous tumor markers have been evaluated to improve 
the sensitivity and specificity of preoperative tests in patients 
suspected of having ovarian cancer. Among many mark-
ers, many published data have shown the usefulness of the 
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Fig. 1. Serum cancer antigen 125, carcinoembryonic antigen, and 
CA125/CEA ratio (CCR) levels in patients with mucinous, serous, 
clear cell, and endometrioid ovarian carcinoma. Values for (A) 
CA125, (B) CEA, and (C) CCR for stage I (left panel) and stages II–
IV (right panel) are shown. Significant values between the groups 
are presented as shown. Values were considered significant when 
P<0.05. 
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antigen CA125, as a reliable serum tumor marker for both 
monitoring and following up patients diagnosed with EOC 
[13-15]. Einhorn et al. [16] reported the potential value of 
CA125 in preoperative diagnosis of ovarian cancers, howev-
er, controversies still exist regarding the clinical relevance of 
CA125 in differentiating pelvic masses [17-20]. In addition, 
Mucinous ovarian carcinoma (II, III, IV)
VS
Other epithelial ovarian carcinoma (II, III, IV)
CA125 CA125
Mucinous ovarian carcinoma (I)
VS
Other epithelial ovarian carcinoma (I)
AUC= 0.6667
AUC= 0.8345
Fig.2.
Mucinous ovarian carcinoma (II, III, IV)
VS
Other epithelial ovarian carcinoma (II, III, IV)
CEA CEA
Mucinous ovarian carcinoma (I)
VS
Other epithelial ovarian carcinoma (I)
AUC= 0.7819 AUC= 0.725
Fig.2.
Mucinous ovarian carcinoma (II, III, IV)
VS
Other epithelial ovarian carcinoma (II, III, IV)
CA125/CEA ratio (CCR) CA125/CEA ratio (CCR)
Mucinous ovarian carcinoma (I)
VS
Other epithelial ovarian carcinoma (I)
AUC= 0.7838
AUC= 0.9167
Fig.2.
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C
Fig. 2. Receiver operating characteristics (ROC) curve for preopera-
tive cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), 
and CA125/CEA ratio (CCR) in ovarian mucinous carcinoma vs. in 
other types of epithelial ovarian carcinoma. ROC curve with area 
under the curve (AUC) values for (A) CA125, (B) CEA and (C) CCR 
for stage I (left panel) and stages II–IV (right panel) are shown. 
Table 2. Sensitivity, specificity, positive predictive value, negative predictive value, and cut-off value for differentiation between mucinous 
carcinoma and other types of epithelial ovarian carcinoma
Statistical data CA125 (U/mL) CEA (ng/mL) CCR
Mucinous ovarian carcinoma (I)
Sensitivity (%) 72.7 95.0 75.0
Specificity (%) 64.5 60.0 77.5
PPV (%) 47.7 51.6 59.7
NPV (%) 83.8 96.3 87.3
Cut-off 35.0 5.0 90.7
Mucinous ovarian carcinoma (II–IV)
Sensitivity (%) 87.5 83.3 100.0
Specificity (%) 77.1 60.0 84.4
PPV (%) 23.5 14.2 14.2
NPV (%) 98.7 97.7 97.7
Cut-off 35.0 5.0 90.7
PPV, positive predictive value; NPV, negative predictive value; CA125, cancer antigen 125; CEA, carcinoembryonic antigen; CCR, CA125/CEA 
ratio.
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CA125 is more often elevated in serous than in mucinous 
carcinomas, and while only 50% of ovarian cancers in stage 
I and II are associated with elevated CA125, this is found 
in 90% of patients at stage IIIc or IV [21-24]. Consistent 
with these data, our study showed that CA125 levels had the 
highest mean values in serous carcinoma (stage I: 235.0 U/mL, 
stage II–IV: 1,709 U/mL), while the lowest values in mucinous 
carcinoma (stage I: 44.2.0 U/mL, stage II–IV: 176.7 U/mL) in all 
study groups. 
The several studies have demonstrated the presence of 
CEA in ovarian mucinous tumors and it is partly because a 
portion of ovarian mucinous cystadenomas contain a popu-
lation of intestinal like cells that resemble those present in 
colonic adenomas [25]. In addition, the ovarian mucinous 
carcinomas contain cells that resemble those found in colon-
ic carcinomas and, there is histochemical similarity between 
the mucins secreted by the intestinal type of ovarian tumors 
and colonic tumors [25,26]. It is therefore, not surprising 
that there is also a similarity in the CEA expression in the 
colonic tumors and the intestinal areas of the ovarian muci-
nous tumors. It has been known that CEA is elevated in ap-
proximately 35% of EOC patients and occurs more often in 
mucinous tumors (88%) than in serous tumors (19%) [27-
30]. Thus, in the current study, we also evaluated the CEA 
levels besides CA125 in different 4 types of EOC. We found 
that the CEA levels in mucinous carcinoma were higher than 
those in other types of EOC in both stages I and II–IV group 
(all P<0.01), with the exception of stage I serous carcinoma. 
It has been previously shown that CCR rather than CA125 
alone could be a useful biomarker in the study with a larger 
proportion of ovarian cancer patients [11]. They also sug-
gested that any patient referred to the hospital with an un-
diagnosed tumor in the pelvis should — in addition to risk 
of malignancy index — be tested by using the CCR <25 as a 
criterion for further examination [11]. In our study, because 
CA125 and CEA level in mucinous carcinomas were signifi-
cantly different from those in other types of EOC, we hy-
pothesized that combination of CA125 and CEA could yield 
a more robust and reliable tool to differentiate between 
ovarian mucinous carcinoma and other EOCs. In the pres-
ent study, the cut-off value of <90.7 achieved high levels of 
sensitivity and specificity to differentiate between mucinous 
and other EOCs for both stage I and II–IV, but particularly 
for stage II–IV. Therefore, we propose to use the CCR (<90.7) 
as a strong preoperative diagnostic tool to differentiate be-
tween mucinous from other types of EOC. 
There are certain limitations for this study such as the 
relatively small numbers of patients with EOC. And the pre-
operative CA125, CEA, CCR according to each stage (II–
IV) cannot be compared between patients with mucinous 
carcinoma and other types of EOC. Therefore, as stage in-
creased, preoperative CA125, CEA, CCR trends according to 
the increase of stage could not be analyzed in this study.
Our study demonstrates that preoperative CCR is a useful 
discriminative marker for mucinous carcinoma from other 
types of EOC. The CCR value <90.7 exhibited high specific-
ity (stage I: 77.5%, stage II–IV: 84.4%) and sensitivity (stage 
I: 75.0%, stage II–IV: 100%) to differentiate ovarian muci-
nous carcinoma from other types of EOCs preoperatively. 
The CCR value <90.7 might provide a superior marker for 
ovarian mucinous carcinoma, especially for advanced stages 
(II–V) disease. Although the information obtained from pre-
operative CCR cannot provide all the needed information to 
diagnosis for ovarian mucinous carcinoma, CCR might be an 
important diagnostic tool to differentiate ovarian mucinous 
carcinoma from other types of EOCs. 
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